Zenas BioPharma raises $225 million through initial public offering

Joe Conroy Partner and Chairman Cooley
Joe Conroy Partner and Chairman - Cooley
0Comments

Zenas BioPharma has launched its initial public offering, raising $225 million. The clinical-stage biopharmaceutical company focuses on developing immunology-based therapies. In the IPO, Zenas issued 13,235,294 shares of common stock at $17 each. Underwriters have a 30-day option to purchase an additional 1,985,294 shares. Trading began on September 13, 2024, on the Nasdaq Global Select Market under the ticker symbol ZBIO.

Cooley LLP advised the underwriters for this IPO. The team was led by lawyers Richard Segal, Denny Won, Div Gupta, and Evan Leitner. Cooley provides legal services in transformative deals and complex regulatory matters with nearly 1,400 lawyers across offices in the United States, Asia, and Europe.



Leave a Reply

Your email address will not be published. Required fields are marked *

Related

Christina Guerola Sarchio President Dechert

Dechert advises Pagaya on $300M inaugural securitization

Dechert has provided advisory services to Pagaya Technologies LTD on its first securitization of point-of-sale loans, known as POSH 2025-1.

David W. Barrett Executive Partner Faegre Drinker

UK introduces ‘failure to prevent fraud’ corporate offence effective September 2025

A new corporate offence of “failure to prevent fraud” is set to be enacted on September 1, 2025.

Gina M. Kastel Chair Faegre Drinker

Supreme Court clarifies NEPA’s scope in Seven County Infrastructure Coalition case

On May 29, 2025, the U.S. Supreme Court issued a decision in the case of Seven County Infrastructure Coalition v. Eagle County, No. 23-975.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from Big Law Reporter.